Pulmonary Arterial Hypertension (PAH) Market

Pulmonary Arterial Hypertension (PAH) Market Outlook (2021-2028)

The pulmonary arterial hypertension (PAH) market was valued at US$ 5.2 Bn in 2020 and is projected to accelerate at a CAGR of 5.4% to reach US$ 13.5 Bn by 2028.

Report Attributes	Details
Pulmonary Arterial Hypertension Market Size (2020)	US$ 5.2 Bn
Projected Year Value (2028)	US$ 13.5 Bn
Global Market Growth Rate (2021-2028)	5.4% CAGR
North America Market Share (2022)	35%
Key Companies Profiled	Gilead Sciences Inc. Pfizer, Inc. GlaxoSmithKline plc Novartis International AG Bayer HealthCare United Therapeutics Corp

Demand for endothelin receptor antagonists (ERAs) is expected to increase at a 5% CAGR over the forecast period.

Revenue Analysis of Pulmonary Arterial Hypertension from 2017-2020 Vs Market Outlook for 2021-2028

“Rapid Deployment of Advanced Technologies for PAH Treatments Fueling Market Expansion”

As per Fact.MR, a market research and competitive intelligence provider, the global pulmonary arterial hypertension market was valued at US$ 5.2 Bn in 2020.

Pulmonary arterial hypertension is a life-threatening medical disorder characterized by high blood pressure in the arteries that connect the heart and lungs. It causes the artery walls to constrict and thicken, increasing the pressure on the heart to pump blood and weakening the muscles.

Shortness of breath, tiredness, and swelling in the ankles and legs are all symptoms of PAH. computed tomography (CT) scans, chest X-rays, ventilation-perfusion and Echocardiography studies are all used to identify it.

One of the primary factors driving the market growth is the rising frequency of cardiovascular diseases and arterial hypertension. Furthermore, the growing senior population, which is more prone to idiopathic pulmonary arterial hypertension (IPAH) and associated pulmonary arterial hypertension (APAH), is fueling market expansion.

Excessive alcohol consumption, a lack of physical activity, and unhealthy dietary choices have all contributed to an increase in the risk of hypertension and high blood pressure. This, together with the development of novel drugs and advanced technologies for PAH treatments such as vasodilators and treprostinil are the factors boosting the market growth.

Other factors, such as increased public awareness of the potential treatment options for heritable pulmonary arterial hypertension and improved healthcare infrastructure around the world, are likely to propel the market.

All of these factors are expected to drive the market at a 5.4% CAGR from 2021 to 2028.

Which Key Trend Will Boost PAH Drug Sales across the World?

“Rising Geriatric Population to Propel Industry Growth”

Prevalence of PAH in the older population is expected to rise over the coming years. One of the non-modifiable factors that increase the risk of heritable pulmonary arterial hypertension (HPAH) is increasing age. Furthermore, due to diastolic dysfunction and age-related blood vessel stiffening, the older population base is susceptible to this ailment, which adds to the business need.

Market firms and government organizations have launched several educational and awareness campaigns to raise arterial hypertension knowledge among healthcare practitioners and patients.

These programs are also advantageous to the elderly population since they increase their level of awareness. Several government organizations, including the WHO, Million Hearts, and others, have launched campaigns to raise awareness and boost company revenue.

What Restraints are Being Faced by PAH Drug Suppliers?

“Side Effects Associated with PAH Drugs & High Cost of PAH Treatment Restraining Market Growth”

The FDA drug approval process is a lengthy procedure that verifies the drug's safety and efficacy. As a result, the industry growth may be hampered by a lengthy regulatory procedure and adverse effects associated with the use of PAH drugs over the projection period.

The market is projected to be restrained by big players terminating medications during clinical studies, patients' unawareness of the prevalence of pulmonary arterial hypertension, and high diagnosis and treatment costs.

Why is North America Expected to Lead the Pulmonary Arterial Hypertension Market?

“Rising Demand for Developed Healthcare Facilities to Boost Market Growth in North America”

North America is projected to account for 35% share of the pulmonary arterial hypertension market in 2022. Rising awareness, a high diagnosis rate, and supportive government measures are expected to drive market growth in North America.

The existence of key competitors and a well-planned reimbursement structure also help the market growth. The demand for developed healthcare facilities associated with pulmonary arterial hypertension is being driven by the increased prevalence of chronic and infectious diseases, as well as a high diagnosis rate.

Country-wise Insights

Why is the U.S. Pulmonary Arterial Hypertension Market Growing at a Rapid Pace?

“Prominent Presence of Board-Certified Physicians Boosting Market Value”

Pulmonary arterial hypertension causes over 200,000 hospitalizations in the United States each year. The availability of board-certified physicians, rising hospital admissions linked to PAH, and the commercialization of new PAH medications, all of which are accompanied by a promising pharmacological pipeline, are driving market expansion in the United States.

Moreover, the U.S. PAH market is predicted to accelerate due to the rising prevalence of this illness due to heavy alcohol consumption, quick adoption of a sedentary lifestyle, and rising smoking habits among individuals.

What is the Demand Outlook for Pulmonary Arterial Hypertension Solutions in India?

“Rising Prevalence of Diabetes to Propel Market Revenue in India”

The market in India is expected to grow at the fastest rate over the forecast period due to its huge population, quick economic development, and improved healthcare systems. In addition, rising initiatives for clinical research development are expected to fuel market growth.

Rise in the adoption of unhealthy diets and an increase in life expectancy are two major variables expected to boost diabetes cases in the country and drive the market. The rising prevalence of diabetes, increased generics consumption, the presence of major pharmaceutical companies, and easy access to high-quality pulmonary arterial hypertension treatments are all expected to drive the market.

Category-wise Insights

Which Drug Class is Likely to Accrue Maximum Market Gains?

“Numerous Therapeutic Advantages Offered by Endothelin Receptor Antagonists to Impel Market Growth”

Endothelin receptor antagonists (ERAs) are predicted to account for around 45% share of the pulmonary arterial hypertension market in 2022.

Endothelin receptor antagonist drugs are widely suggested as a targeted therapy for reversing heart and lung damage, slowing PAH progression, and dilation of blood vessels, among other things. Clinical studies have shown that people with pulmonary arterial hypertension produce a lot of endothelin, which causes high blood pressure.

Physicians frequently prescribe endothelin receptor antagonists to lessen the amount of endothelin in the blood vessels. Furthermore, increasing investments in research and development efforts to offer new ERAs are expected to boost the market growth.

COVID-19 Impact on Pulmonary Arterial Hypertension Treatment Demand

The COVID-19 pandemic had a significant impact on the pulmonary arterial hypertension market. Market circumstances became unpredictable as a result of the pandemic, which hindered expansion.

COVID-19 caused supply chain issues, clinical trial delays, regulatory review delays, operational obstacles, patient access restrictions, and a drop in demand. Other obstacles to the industry growth included delays in diagnostic testing, revised hospital and emergency care protocols, and a disrupted drug supply chain.

Market participants reacted to the COVID-19 outbreak by launching a variety of measures. These included, among other things, maintaining a stable financial position, keeping an adequate supply of products, implementing procedures to ensure uninterrupted distribution to patients, and engaging in R&D activities.

Regulatory agency approvals of supportive products, such as extended indications of use, first generics approval, approval of medication delivery systems, and so on, are expected to fuel market expansion over the coming years.

Competitive Landscape

For business expansion, prominent participants are implementing strategic formulations such as new product development and commercialization, commercial expansion, and distribution partnerships. Furthermore, these leaders are substantially investing in product development, which is fueling revenue generation.

For instance,

• In 2019, In the United States, Teva Pharmaceutical Industries Ltd. introduced a generic version of Gilead's Letairis (ambrisentan) tablets. The endothelin receptor antagonist ambrisentan is used to treat pulmonary arterial hypertension.

Key Segments Covered in Pulmonary Arterial Hypertension Industry Research

• By Drug Class:

  • Prostacyclin & Prostacyclin Analogs
  • Endothelin Receptor Antagonists (ERAs)
  • Phosphodiesterase-5 (PDE-5) Inhibitors
  • Soluble Guanylate Cyclase (sGC) Stimulators

• By Pipeline Analysis:

  • Early-stage Drug Candidates (Phase I & Phase II)
  • Late-stage Drug Candidates (Phase III & Registration Phase)

• By Region:

  • North America 
  • Europe 
  • Asia Pacific 
  • Latin America 
  • Middle East & Africa